What is Carevive STAIRS and how does it impact patients and care teams?

Maddie Herzfeld, one of the co-founders of Carevive, excitedly announces the launch of Carevive STAIRS – the first-ever computerized cancer symptom pathways designed specifically for oncology nurses.

As an oncology nurse herself for the past 25 years, Maddie takes immense pride in this innovative product that empowers nurses to work at the top of their license. Carevive STAIRS, developed with input from expert oncology nurse panels across the country, enables early symptom detection and proactive management using the latest evidence, thereby preventing treatment disruptions and hospitalizations.

The product’s development was supported by the National Cancer Institute, and Carevive extends gratitude to the dedicated oncology nurses and their exceptional team who brought this groundbreaking tool to life. To see the difference Carevive STAIRS can make in your cancer program, reach out to their sales team for a demo. Get ready to elevate your patient care with Carevive STAIRS!

Recent Episodes

The sterile processing industry stands at a pivotal moment. With surgical case volumes rising while departmental resources remaining flat, the pressure to “do more with less” has never been greater. Nowadays, sterile processing departments (SPDs) are struggling with high staff turnover and growing compliance requirements. And while these regulations are designed to improve patient…

With the healthcare landscape seeing many evolving changes, employee engagement is no longer just a buzzword — it’s now a business imperative. Amid rising turnover and persistent staffing shortages, organizations are under pressure to build resilient, engaged teams. According to Gallup, 70% of the variance in team engagement is tied to one factor: the…

Pharmaceutical manufacturers are under increasing pressure to deliver sterile, high-quality medicines in smaller batches and faster cycles. As pharma manufacturing evolves, regulatory demands have intensified, especially following the 2023 revision of EU GMP Annex I, which places new emphasis on contamination control strategies, improved traceability, and minimizing human intervention throughout production. According to American…